$246 Million is the total value of Iguana Healthcare Management, LLC's 82 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Exit | ARIAD PHARMACEUTICALS INCcall | $0 | – | -50,000 | -100.0% | -0.12% | – | |
| Exit | ACCELERATE DIAGNOSTICS INCcall | $0 | – | -25,000 | -100.0% | -0.13% | – | |
| Exit | DERMIRA INCput | $0 | – | -20,000 | -100.0% | -0.15% | – | |
| FWP | Exit | FORWARD PHARMA A/Ssponsored adr | $0 | – | -30,000 | -100.0% | -0.19% | – |
| ARIA | Exit | ARIAD PHARMACEUTICALS INC | $0 | – | -100,000 | -100.0% | -0.23% | – |
| CSII | Exit | CARDIOVASCULAR SYS INC DEL | $0 | – | -75,000 | -100.0% | -0.28% | – |
| RXDX | Exit | IGNYTA INC | $0 | – | -125,000 | -100.0% | -0.31% | – |
| PBYI | Exit | PUMA BIOTECHNOLOGY INC | $0 | – | -30,000 | -100.0% | -0.32% | – |
| HTWR | Exit | HEARTWARE INTL INC | $0 | – | -30,000 | -100.0% | -0.35% | – |
| Exit | SAREPTA THERAPEUTICS INCcall | $0 | – | -50,000 | -100.0% | -0.36% | – | |
| Exit | ONCOMED PHARMACEUTICALS INCcall | $0 | – | -100,000 | -100.0% | -0.37% | – | |
| BLUE | Exit | BLUEBIRD BIO INC | $0 | – | -25,000 | -100.0% | -0.39% | – |
| TNET | Exit | TRINET GROUP INC | $0 | – | -75,000 | -100.0% | -0.39% | – |
| PETX | Exit | ARATANA THERAPEUTICS INC | $0 | – | -200,000 | -100.0% | -0.40% | – |
| LDRH | Exit | LDR HLDG CORP | $0 | – | -60,000 | -100.0% | -0.56% | – |
| Exit | ALNYLAM PHARMACEUTICALS INCput | $0 | – | -25,000 | -100.0% | -0.58% | – | |
| IPXL | Exit | IMPAX LABORATORIES INC | $0 | – | -50,000 | -100.0% | -0.59% | – |
| Exit | MEDIVATION INCcall | $0 | – | -35,000 | -100.0% | -0.59% | – | |
| Exit | GW PHARMACEUTICALS PLCcall | $0 | – | -25,000 | -100.0% | -0.66% | – | |
| BKD | Exit | BROOKDALE SR LIVING INC | $0 | – | -125,000 | -100.0% | -0.73% | – |
| BMRN | Exit | BIOMARIN PHARMACEUTICAL INC | $0 | – | -30,000 | -100.0% | -0.91% | – |
| Exit | MERCK & CO INC NEWput | $0 | – | -50,000 | -100.0% | -0.97% | – | |
| DVAX | Exit | DYNAVAX TECHNOLOGIES CORP | $0 | – | -140,000 | -100.0% | -0.99% | – |
| REGN | Exit | REGENERON PHARMACEUTICALS | $0 | – | -7,500 | -100.0% | -0.99% | – |
| Exit | REGENERON PHARMACEUTICALSput | $0 | – | -7,500 | -100.0% | -0.99% | – | |
| Exit | INCYTE CORPcall | $0 | – | -40,000 | -100.0% | -1.06% | – | |
| Exit | BRISTOL MYERS SQUIBB COcall | $0 | – | -50,000 | -100.0% | -1.17% | – | |
| Exit | BIOGEN INCcall | $0 | – | -20,000 | -100.0% | -1.91% | – | |
| LLY | Exit | LILLY ELI & CO | $0 | – | -75,000 | -100.0% | -1.98% | – |
| MDT | Exit | MEDTRONIC PLC | $0 | – | -100,000 | -100.0% | -2.75% | – |
| Exit | SPDR S&P 500 ETF TRput | $0 | – | -50,000 | -100.0% | -3.76% | – | |
| Exit | ISHARES TRput | $0 | – | -100,000 | -100.0% | -4.05% | – | |
| Exit | SPDR SERIES TRUSTput | $0 | – | -250,000 | -100.0% | -4.73% | – | |
| CI | Exit | CIGNA CORPORATION | $0 | – | -100,000 | -100.0% | -5.03% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2016-11-04
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC | 17 | Q1 2018 | 7.5% |
| ULTRAGENYX PHARMACEUTICAL IN | 17 | Q1 2018 | 6.7% |
| MERCK & CO INC NEW | 16 | Q1 2018 | 5.4% |
| CELGENE CORP | 15 | Q4 2017 | 7.9% |
| AERIE PHARMACEUTICALS INC | 15 | Q4 2017 | 3.3% |
| GILEAD SCIENCES INC | 14 | Q1 2017 | 6.7% |
| ESPERION THERAPEUTICS INC NE | 14 | Q1 2018 | 7.8% |
| SUPERNUS PHARMACEUTICALS INC | 14 | Q4 2017 | 2.8% |
| DERMIRA INC | 14 | Q1 2018 | 2.7% |
| AMGEN INC | 13 | Q1 2017 | 6.5% |
View Iguana Healthcare Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2018-05-15 |
| 13F-HR | 2018-02-14 |
| 13F-HR/A | 2017-11-16 |
| 13F-HR | 2017-11-14 |
| 13F-HR | 2017-08-14 |
| 13F-HR | 2017-05-15 |
| 13F-HR | 2017-02-14 |
| 13F-HR/A | 2016-11-17 |
| 13F-HR | 2016-11-14 |
| 13F-HR/A | 2016-11-04 |
View Iguana Healthcare Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.